AIDA Publishes Major AI Breakthrough in Nature Communications

AIDA researchers have published a significant scientific advance in Nature Communications: an AI-powered “Clinician” capable of recommending personalised treatment for Helicobacter pylori (H. pylori), the leading cause of gastric cancer worldwide.

The system was developed using reinforcement learning and trained on real-world data from more than 38,000 patients in the European Hp-EuReg registry. The results are striking. AI-recommended therapies showed a 94.1% eradication success rate, compared with 88.1% for standard treatment.

This innovative approach does not replace doctors but strengthens clinical decision-making. By analysing thousands of patient profiles and treatment pathways, the AI provides evidence-based recommendations tailored to each individual. The system is currently being evaluated for integration into future clinical workflows.

This achievement marks an important step in AIDA’s mission to reduce gastric cancer burden through advanced diagnostic and therapeutic tools powered by artificial intelligence.

Read the full article

Share

You might also be interested in

en

AIDA at ESMO GI Congress and DiCE’s Masterclass

AIDA proudly participated in the ESMO Gastrointestinal Cancers Congress and the Digestive Cancers Europe Masterclass, joining leading clinicians, researchers, and patient advocates to discuss the future of digestive cancer prevention.

en

AIDA Partner LU KPMI Represents Europe at HUG 2025 in Seoul

From 20–22 March, AIDA partner LU KPMI (University of Latvia) participated in the HUG 2025 Symposium in Seoul, South Korea, one of the leading international meetings focused on Helicobacter pylori and upper gastrointestinal diseases.